Effect at One Year of Adjuvant Trastuzumab for HER2+ Breast Cancer Combined with Radiation or an Anthracycline on Left Ventricular Ejection Fraction

To determine the impact of radiation therapy (XRT) in addition to trastuzumab (TZB) adjuvant chemotherapy for HER2+ breast cancer on left ventricular systolic function, we assessed demographics, oncologic treatment history including XRT exposure, and serial measurements of left ventricular ejection fraction (LVEF) in 135 consecutively identified women receiving TZB for treatment of adjuvant breast cancer. Longitudinal mixed effects models were fit to identify baseline to treatment changes in LVEF among those receiving TZB with or without concomitant anthracycline or XRT.

Source: The American Journal of Cardiology - April 1, 2020 Category: Cardiology Authors: Mousumi M. Andersen, Jessie Bowers, Banks W. Kooken, Ralph B. D'Agostino, Jennifer H. Jordan, Sujethra Vasu, Alexandra Thomas, Heidi D. Klepin, Doris R. Brown, W. Gregory Hundley Source Type: research